<code id='EDFFCD8281'></code><style id='EDFFCD8281'></style>
    • <acronym id='EDFFCD8281'></acronym>
      <center id='EDFFCD8281'><center id='EDFFCD8281'><tfoot id='EDFFCD8281'></tfoot></center><abbr id='EDFFCD8281'><dir id='EDFFCD8281'><tfoot id='EDFFCD8281'></tfoot><noframes id='EDFFCD8281'>

    • <optgroup id='EDFFCD8281'><strike id='EDFFCD8281'><sup id='EDFFCD8281'></sup></strike><code id='EDFFCD8281'></code></optgroup>
        1. <b id='EDFFCD8281'><label id='EDFFCD8281'><select id='EDFFCD8281'><dt id='EDFFCD8281'><span id='EDFFCD8281'></span></dt></select></label></b><u id='EDFFCD8281'></u>
          <i id='EDFFCD8281'><strike id='EDFFCD8281'><tt id='EDFFCD8281'><pre id='EDFFCD8281'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:Wikipedia    - browse:8
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore